SCHEMBL7089254

SCHEMBL7089254

CCC(c1ccc2c(c1)NC(=S)C(C)O2)N(Cc1cccs1)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.35
NPSR1 Q6W5P4 3/20 0.35
GAA P10253 2/20 0.35
POLB P06746 1/20 0.34
TRPM8 Q7Z2W7 6/20 0.33
RIPK1 Q13546 1/20 0.33
ALDH1A1 P00352 6/20 0.32
TP53 P04637 2/20 0.31
YAP1 P46937 1/20 0.31
TEAD4 Q15561 1/20 0.31
LMNA P02545 3/20 0.31
MAPT P10636 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PKM P14618 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711223 0.92 PARP1 (0.38) HTTNPSR1GAAPOLBTRPM8
SCHEMBL7088859 0.87 PARP1 (0.37) HTTPOLBTRPM8ALDH1A1LMNA
SCHEMBL7708174 0.82 GAA (0.37) HTTNPSR1GAAPOLBTRPM8
SCHEMBL7708180 0.81 HTT (0.34) HTTNPSR1GAAPOLBTRPM8
SCHEMBL7708101 0.79
SCHEMBL7704922 0.79 PARP1 (0.48) HTTALDH1A1L3MBTL1HSD17B10
SCHEMBL7710837 0.77 PARP1 (0.40) HSD17B10
SCHEMBL7093398 0.73 PARP1 (0.41) HTTPOLBTRPM8ALDH1A1LMNA
SCHEMBL7708013 0.73 CHRNB2 (0.30)
SCHEMBL5189562 0.73 PARP1 (0.35) L3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed